Validation and performance comparison of two SARS-CoV-2 IgG/IgM rapid tests

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease called COVID-19. COVID-19 is primarily diagnosed using molecular techniques mainly real-time reverse transcriptase PCR. Reliable and accurate serologic assays for COVID-19, are an important tool for surveillance and epidem...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Awaji, Nisreen Naser, Ahmedah, Hanadi Talal, Alsaady, Isra Mohammed, Bawaked, Rowaedh Ahmed, Alraey, Mohammed A., Alasiri, Ahmed Ayed, Alfaifi, Abdullah Mofareh, Alshehri, Hamdan Ali, Alserihi, Raed, Yasin, Elrashed B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955801/
https://www.ncbi.nlm.nih.gov/pubmed/33746537
http://dx.doi.org/10.1016/j.sjbs.2021.03.007
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease called COVID-19. COVID-19 is primarily diagnosed using molecular techniques mainly real-time reverse transcriptase PCR. Reliable and accurate serologic assays for COVID-19, are an important tool for surveillance and epidemiologic studies. In this study, the IgG/IgM Rapid Test Cassette and the Prima COVID-19 IgG/IgM Rapid Test for the detection of SARS-CoV-2 antibodies in blood, serum and plasma samples collected from patients up to 48 days after symptom onset in Saudi Arabia were validated. Overall, both tests showed poor performance and cannot be utilised for COVID-19 diagnosis as a point of care test or to determine seroprevalence.

Ejemplares similares